Peanut Allergy Treatment Market Overview Highlights Strong Growth Potential
The global Peanut Allergy treatment market is witnessing substantial growth driven by increasing awareness, improved diagnostic methods, and expanding therapeutic options. According to current market analysis, the Peanut Allergy treatment market across the seven major markets (7MM) – the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan – was valued at approximately USD 533 million in 2025. With the growing burden of food allergies and the emergence of innovative therapies, the market is expected to experience remarkable expansion.
Forecast projections indicate that the Peanut Allergy treatment market will grow at a compound annual growth rate (CAGR) of 18.50% between 2025 and 2034, reaching an estimated USD 2,464 million by 2034. The United States currently represents the largest market share due to high prevalence rates, strong healthcare infrastructure, and early adoption of novel therapeutics. Increased research activity, expanding clinical pipelines, and regulatory support are also accelerating the development of advanced treatment strategies for peanut allergy.
Peanut Allergy Market Landscape and Epidemiology Trends Continue to Evolve
The Peanut Allergy treatment market landscape is evolving rapidly as pharmaceutical companies intensify efforts to develop more effective and convenient therapies. Several companies are conducting clinical trials focused on improving desensitization, preventing severe allergic reactions, and enhancing long-term tolerance.
Leading pharmaceutical and biotechnology firms actively involved in Peanut Allergy clinical development include DBV Technologies with the Viaskin (DBV712) Peanut Patch, Novartis with Remibrutinib, Aravax with PVX108, ALK-Abello with Sublingual Immunotherapy Tablet, InnoUp Farma with INP20, Allergy Therapeutics with VLP Peanut, Intrommune Therapeutics with INT301, and Regeneron Pharmaceuticals developing Linvoseltamab combined with Dupilumab.
Peanut allergy remains one of the most common and potentially severe food allergies worldwide. Over the past several decades, its prevalence has steadily increased, particularly among children and adolescents. Symptoms of peanut allergy frequently appear early in life, often as early as four months of age, and most commonly within the first two years of life.
Although peanut allergy tends to persist throughout life for many individuals, approximately 20% of children naturally outgrow the condition as they grow older. Epidemiological trends also indicate gender-related differences in prevalence. While males tend to have a higher prevalence before puberty, females are more likely to develop adult-onset peanut allergy after puberty.
In the United States, peanut allergy ranks among the top nine food allergies, affecting roughly 1–2% of the total population. Across the seven major markets, the diagnosed prevalent population reached approximately 9.8 million cases in 2024, with the United States accounting for the largest share of these cases.
Market Size and Forecast Demonstrate Strong Expansion Prospects
The Peanut Allergy treatment market is expected to expand significantly over the coming decade as innovative therapeutic approaches reach commercialization. Increasing diagnosis rates, enhanced awareness, and improved patient access to treatment options are key factors contributing to market growth.
The market was valued at USD 533 million in 2025 and is projected to reach USD 2,464 million by 2034, reflecting strong momentum in the development and adoption of targeted therapies. The projected 18.50% CAGR highlights the growing demand for effective management strategies for peanut allergy patients.
Among the seven major markets, the United States remains the dominant contributor, largely due to higher prevalence, favorable reimbursement policies, strong regulatory pathways, and active clinical research programs. Europe and Japan are also witnessing gradual market expansion as awareness and diagnostic capabilities continue to improve.
Key Drivers Supporting the Expansion of the Peanut Allergy Market
- One of the primary drivers fueling the growth of the Peanut Allergy treatment market is the rising global prevalence of peanut allergy. This condition typically emerges during early childhood and remains persistent for many patients throughout adulthood. Early onset combined with long-term disease burden significantly increases the need for effective therapies and long-term management strategies.
- In 2024, the diagnosed prevalent population of peanut allergy across the seven major markets reached approximately 9.8 million individuals, highlighting the growing public health burden associated with food allergies. Younger populations continue to represent the largest patient pool, making pediatric treatment solutions particularly important for future market expansion.
- Another important growth driver is the increasing availability of approved therapeutic options. Currently, PALFORZIA and XOLAIR represent the only approved drug therapies specifically targeting peanut allergy. These treatments offer healthcare providers and patients valuable options for managing allergic reactions and improving tolerance to peanut exposure.
- PALFORZIA is currently the only oral immunotherapy treatment available for peanut allergy. It is approved for children aged 1–3 years and 4–17 years and works by gradually desensitizing the immune system to peanut proteins. However, its effectiveness requires continuous daily dosing to maintain tolerance, which presents challenges related to adherence and convenience.
- XOLAIR, on the other hand, is approved for individuals aged one year and older and works by targeting immunoglobulin E (IgE), a key component involved in allergic reactions. In March 2025, the US Food and Drug Administration approved OMLYCLO (omalizumab-igec) as the first biosimilar designated as interchangeable with XOLAIR for the treatment of IgE-mediated food allergies, expanding accessibility and affordability for patients.
Understanding the Pathophysiology of Peanut Allergy
Peanut allergy is caused by an abnormal immune response to proteins found in peanuts. The condition is typically mediated by immunoglobulin E (IgE), which plays a central role in allergic reactions. When individuals with peanut allergy are exposed to peanut proteins, their immune system mistakenly identifies these proteins as harmful.
During the initial exposure to peanut allergens, specialized immune cells known as T helper type 2 (Th2) cells become activated and release cytokines that stimulate the production of IgE antibodies. These antibodies bind to receptors on mast cells and basophils, effectively priming the immune system for future reactions.
Upon subsequent exposure to peanut allergens, these IgE antibodies recognize the allergen and trigger the activation of mast cells and basophils. This activation leads to the release of inflammatory mediators such as histamine, leukotrienes, and cytokines, which cause symptoms including swelling, itching, hives, respiratory distress, and in severe cases, anaphylaxis.
Compared with many other food allergies, peanut allergy is associated with a higher risk of severe allergic reactions and anaphylaxis-related fatalities, making effective management and prevention strategies essential for patient safety.
Advances in Peanut Allergy Diagnostic Approaches
Accurate diagnosis is essential for effective management of peanut allergy. The diagnostic process typically begins with a thorough clinical history, which helps physicians evaluate symptoms, exposure patterns, and potential triggers. Clinical history remains the most critical component of the diagnostic process because it provides context for interpreting test results.
The double-blind, placebo-controlled food challenge (DBPCFC) is considered the gold standard for diagnosing food allergies. However, because it involves controlled exposure to allergens, it is usually performed only in specialized medical settings under close supervision.
Several additional diagnostic tests are commonly used to evaluate peanut allergy sensitization. Skin Prick Testing (SPT) and serum specific IgE testing are widely used first-line diagnostic tools due to their relatively low cost and rapid results. These tests are highly sensitive and have strong negative predictive value, but they may produce false positives or false negatives when used alone.
Emerging diagnostic technologies are further improving the accuracy of allergy testing. Molecular allergy diagnostics, basophil activation tests, and bead-based epitope assays are increasingly used to provide deeper insights into immune responses and allergen sensitivities. Advances in artificial intelligence and genetic testing are also expected to transform the future of allergy diagnostics.
Current Treatment Strategies for Managing Peanut Allergy
Management of peanut allergy typically involves a multifaceted approach aimed at preventing allergic reactions and improving patient safety. Historically, strict avoidance of peanuts and peanut-containing foods has been the primary strategy for preventing allergic reactions.
Patients diagnosed with peanut allergy are often advised to carry epinephrine auto-injectors, which are used to treat severe allergic reactions such as anaphylaxis. Immediate administration of intramuscular epinephrine remains the only definitive emergency treatment for life-threatening allergic reactions.
Recent clinical guidelines have introduced a major shift in prevention strategies by recommending the early introduction of peanut-containing foods between four and six months of age, even in infants considered at high risk. Studies have shown that early introduction significantly reduces the likelihood of developing peanut allergy later in childhood.
Immunotherapy approaches are also gaining traction as promising treatment options. These include oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). These methods aim to gradually desensitize the immune system by exposing patients to small, controlled amounts of peanut proteins.
Epidemiological Insights Reveal the Burden of Peanut Allergy
- Epidemiological studies provide valuable insights into the distribution and severity of peanut allergy across global populations. In 2024, the total diagnosed prevalent cases of peanut allergy across the seven major markets reached approximately 9.8 million cases.
- The United States reported the highest number of diagnosed cases, with around 5.1 million individuals affected. Within Europe, Germany recorded the highest prevalence among the EU4 countries and the United Kingdom, with approximately 1.1 million diagnosed cases.
- Age-specific analyses indicate that certain adult populations, particularly those aged 41–64 years, represent a significant proportion of diagnosed cases in Japan. Severity distribution data suggest that mild and moderate cases are slightly more common than severe cases, although severe reactions remain a major clinical concern.
- Gender-specific data show that peanut allergy cases are more prevalent in females than males, particularly in adulthood.
Recent Breakthroughs and Industry Developments Accelerating Innovation
- Recent years have witnessed significant progress in peanut allergy research and therapeutic development. In November 2024, Aravax established a new subsidiary in the United Kingdom at Oxford Science Park, strengthening its global presence in food allergy research.
- In December 2024, DBV Technologies reported successful communication with the FDA regarding a regulatory pathway for accelerated approval of the Viaskin Peanut Patch in toddlers aged one to three years. This development represents an important milestone in advancing epicutaneous immunotherapy.
- During the same month, ALK announced positive interim results from its Phase I/II clinical trial evaluating a sublingual immunotherapy tablet designed for peanut allergy treatment.
- Another major regulatory development occurred in January 2025, when the European Commission approved an expanded indication for PALFORZIA covering toddlers aged one to three years across all European Union member states and several European Economic Area countries.
Marketed Drugs and Emerging Therapies Expanding Treatment Options
Currently, the peanut allergy treatment market includes two major approved drugs: PALFORZIA and XOLAIR. PALFORZIA represents the first oral immunotherapy approved specifically for peanut allergy, while XOLAIR targets IgE-mediated allergic responses and can reduce the severity of reactions.
Despite the availability of these therapies, limitations such as side effects, complex dosing schedules, and accessibility challenges continue to restrict widespread adoption. These limitations highlight the need for new therapies that offer improved convenience, safety, and long-term efficacy.
Several promising drugs are currently in development. The Viaskin Peanut Patch from DBV Technologies is designed to deliver small amounts of peanut protein through the skin, allowing gradual desensitization without oral ingestion.
Another innovative therapy under investigation is Remibrutinib, a highly selective Bruton’s Tyrosine Kinase inhibitor being developed by Novartis. This therapy targets immune signaling pathways that contribute to allergic reactions and may offer a new mechanism for controlling food allergies.
Conclusion
The Peanut Allergy treatment market is entering a period of rapid transformation driven by scientific innovation, growing disease prevalence, and increased awareness of food allergies. With the market expected to grow from USD 533 million in 2025 to USD 2,464 million by 2034, the sector presents significant opportunities for pharmaceutical companies, healthcare providers, and investors.
Advances in immunotherapy, emerging drug classes such as BTK inhibitors, and improved diagnostic technologies are reshaping the treatment landscape. As research continues to uncover new therapeutic strategies, the future of peanut allergy management is expected to focus on long-term tolerance, improved patient safety, and enhanced quality of life for millions of affected individuals worldwide.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumarE-mail:abhishek@delveinsight.com
